Making cannabis medicine work better inside your body

This study represents a significant advancement in making cannabis-based medicines more effective and practical for patients. Researchers created tiny microparticles using alginate, a natural polymer from seaweed, to encapsulate bioactive compounds from Cannabis sativa chemotype II (a cannabis variety high in CBD and low in THC). The problem they were solving is crucial: cannabis compounds have very poor absorption when taken orally, meaning much of the dose is wasted. By wrapping these compounds in protective microparticles and coating them with biopolymers like chitosan and pectin, the researchers dramatically improved how much of the cannabinoids actually reach the bloodstream.

The results are impressive from a pharmaceutical standpoint. The optimized formulation achieved encapsulation efficiency of 78.8% for CBD and 46.5% for THC, meaning most of the active compounds were successfully trapped inside the particles. The microparticles maintained high total cannabinoid content up to 21.36% w/w and featured uniform, small sizes ideal for absorption. Importantly, the coatings provided significant protection against degradation, though light exposure still caused some THC breakdown—a practical concern for long-term storage.

What makes this particularly exciting is the pH-dependent release profile: the coated particles released cannabinoids slowly in acidic stomach conditions but faster in neutral intestinal environments, mimicking the ideal drug delivery pathway. This three-phase release pattern means patients could take fewer doses to achieve therapeutic effects, improving treatment compliance and reducing side effects from inconsistent blood levels. While still in the laboratory testing phase, this encapsulation technology could transform how cannabis-derived medicines are manufactured and delivered to patients."